Graphical abstract depicting the results of a Bayesian network meta-analysis of the risk of dementia and Alzheimer’s disease (AD) associated with antidiabetic drugs (IMAGE)

Elsevier

Graphical abstract depicting the results of a Bayesian network meta-analysis of the risk of dementia and Alzheimer’s disease (AD) associated with antidiabetic drugs

Caption

Results show that the first-line antidiabetic drug metformin and the second-line sodium glucose co-transporter-2 (SGLT-2) inhibitors lower the risk of dementia and AD. Sulfonylureas significantly increased the risk in women. In patients aged 75 and over DPP4i, metformin, SGLT-2i and sulfonylureas increased the risk. Analysis includes stratification of patient-specific factors, including age, sex, comorbidity, BMI and baseline A1C.

Credit

American Journal of Preventive Medicine

Usage Restrictions

Please include attribution.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.